Bavarian terminates HPV and HBV collaboration with Janssen
A partnership concerning four diseases with Johnson & Johnson’s pharmaceutical division has been been halved, as Bavarian Nordic has halted its HPV and HBV projects.
by marketwire, translated by daniel pedersen
Bavarian Nordic has ended collaborations with Janssen, the pharmaceutical arm of Johnson & Johnson, in the disease areas of HPV and hepatitis B (HBV), the company reports in its first quarterly report of the year, released on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic maintains 2022 guidance
For subscribers
